Alimera Sciences, Inc. (ALIM)
(Delayed Data from NSDQ)
$8.24 USD
-0.17 (-2.02%)
Updated Dec 13, 2019 03:56 PM ET
3-Hold 3
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
| Zacks Rank | Definition | Annualized Return |
|---|---|---|
| 1 2 3 4 5 S&P |
Strong Buy Buy Hold Sell Strong Sell 500 |
24.63% 17.80% 9.42% 5.10% 2.04% 10.70% |
Zacks Rank Education - Learn about the Zacks Rank
Zacks Rank Home - Zacks Rank resources in one place
Zacks Premium - The only way to fully access the Zacks Rank
D Value | D Growth | F Momentum | F VGM
The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.
The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.
| Value Score | A |
|---|---|
| Growth Score | A |
| Momentum Score | A |
| VGM Score | A |
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
Zacks Style Scores Education - Learn more about the Zacks Style Scores
The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.
The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.
The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.
Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.
The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.
The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.
Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank
Alimera Sciences, Inc. (ALIM) Quote Overview » More Research » Alimera Sciences, Inc. (ALIM) Broker Reports
Brokerage Reports
The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.
The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.
| Value Score | A |
|---|---|
| Growth Score | A |
| Momentum Score | A |
| VGM Score | A |
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
Zacks Style Scores Education - Learn more about the Zacks Style Scores
The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.
The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.
The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.
Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.
0 items in cart
Alimera Sciences, Inc. [ALIM]
Reports for Purchase
Showing records 1 - 20 ( 63 total )
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
3Q19 Financial Results Reported; Reiterate Buy; Reducing PT to $1
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Price: 10.00
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Price: 25.00
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Preliminary Top-Line Revenue for 3Q19 Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Price: 25.00
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Imminent Launch of ILUVIEN in Germany for Uveitis; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Price: 25.00
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
2Q19 Results Disappoint Due to Sales Force Turnover; Reiterate Buy; Lowering PT to $1.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Price: 25.00
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
UK NICE Issues Positive Coverage Decision in Posterior Uveitis; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Price: 10.00
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
1Q19 Financial Results Reported; Reiterate Buy; Raising Price Target to $3
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 25.00
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
ILUVIEN Approved for Posterior Uveitis in Europe; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 10.00
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
ILUVIEN Reimbursement Secured in France; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 10.00
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
2018 Financial Results Reported; Reiterate Buy and Raise Price Target to $2.75
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 25.00
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Record Revenues in 4Q18 and Full-Year 2018; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 10.00
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
New Chief Executive Officer Appointed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 25.00
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Iluvien Secures Regulatory Approval in Canada; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 10.00
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
3Q18 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 25.00
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Preferred Stock Exchange Has No Effect on Earnings; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 10.00
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Iluvien End User Demand Grew 12% YoY in 2Q18; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 25.00
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Iluvien Reimbursement in UK May Expand to Phakic Patients; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 25.00
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
1Q18 Financial Results Reported; Reiterate Buy and Lowering Price Target to $2.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 25.00
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Price: 10.00
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
European Submission for Posterior Uveitis Accepted; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 25.00